Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
27 September 2017

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Sun Pharmaceuticals Industries Ltd (Pharmaceuticals - Indian - Bulk Drugs & Formln)

Last Price 507.60
Net Changes 1.65
Volume 3615167
Prev Close 505.95
507.60 1.65 (0.33%)
Date: Sep 26,2017 EOD




Index Details Pharmaceuticals - Indian - Bulk Drugs & Formln


Chart

Stock Price Details

Market Statistics

Open Price 505 Div Yield (%) 0.69
Buy (Size) 0.00(×0) Eps(Rs) 0
Sell (Size) 0.00(×0) Book Value(Rs) 86.9897469
Buy Quantity 0 Market Cap(Rs.Cr) 121752.83
Sell Quantity 0 Face Value(Rs) 1
Today's High 515 Market Lot 1
Today's Low 504.55 AGM Date Sep
52-Week High 784.75 Book Closure Date Sep
52-Week Low 433.15 ISIN No. INE044A01036

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 0 0.00
Indian (Promoter & Group) 1304855381 54.38
Total of Promoter 1304855381 54.38
Non Promoter (Institution) 782182301 32.60
Non Promoter (Non-Institution) 312238629 13.01
Total Non Promoter 1094420930 45.61
Total Promoter & Non Promoter 2399276311 100.00
Custodians(Against Depository Receipts) 29870 0.00
Grand Total 2399306181 100.00

Company News

20-Sep-2017  Sun Pharmaceuticals Industries gets approval for new label for...
Sun Pharmaceuticals Industries gets approval for new label for Odomzo®

Sun Pharmaceuticals Industries has received approval from the US Food and Drug Administration (USFDA) for a new label for Odomzo® (sonidegib), an oral hedgehog inhibitor indicated for the treatment of patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

Odomzo® was approved by the FDA in July 2015, based on 12-month follow-up results from the pivotal Phase II Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) clinical trial, a multicenter, double-blind study involving 194 patients with laBCC and 36 patients with metastatic basal cell carcinoma (mBCC). The new label now incorporates long-term data from the 30-month analysis of BOLT trial, in which Odomzo® continued to show sustained durable tumor response of 26 months with no new safety concerns.

20-Sep-2017  Sun Pharmaceutical Industries Limited - Press Release
Sun Pharmaceutical Industries Limited - Press Release

Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated September 20, 2017, titled 'Sun Pharma Odomzo. (Sonidegib) New Label Approval Shows Sustained Duration of Response of 26 Months in Treatment of Locally Advanced Basal Cell Carcinoma'.
11-Sep-2017  Other announcement of Sun Pharmaceutical Industrie
Other announcement of Sun Pharmaceutical Industrie

Approval of Scheme of Arrangement among Sun Pharma Medisales Private Limited, Ranbaxy Drugs Limited, Gufic Pharma Limited, Vidyut Investments Limited and Sun Pharmaceutical Industries Limited and their respective members and creditors and filing of E-form INC 28 with Registrar of Companies.
11-Sep-2017  Sun Pharmaceutical Industries Limited - Amalgamation/Merger
Sun Pharmaceutical Industries Limited - Amalgamation/Merger

Sun Pharmaceutical Industries Limited has informed the Exchange regarding Approval of Scheme of Arrangement among Sun Pharma Medisales Private Limited, Ranbaxy Drugs Limited, Gufic Pharma Limited, Vidyut Investments Limited and Sun Pharmaceutical Industries Limited and their respective members and creditors and filing of E-form INC-28 with Registrar of Companies
07-Sep-2017  Sun Pharmaceutical Industries Limited - Updates
Sun Pharmaceutical Industries Limited - Updates

Sun Pharmaceutical Industries Limited has informed the Exchange regarding Submission of Newspaper advertisement under Regulation 30 read with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
06-Sep-2017  Other announcement of Sun Pharmaceutical Industrie
Other announcement of Sun Pharmaceutical Industrie

Submission of Newspaper advertisement under Regulation 30 read with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 read with Schedule III and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have published an advertisement, regarding i) Notice of the 25th Annual General Meeting of the Company to be held on Tuesday, September 26, 2017 for the financial year 2016-17, ii) E-voting and iii) Book Closure, in all the editions of Financial Express dated September 04, 2017 and in Ahmedabad Edition (Gujarati Language) of Financial Express dated September 04, 2017. We are enclosing herewith copy of the advertisement published in the following newspapers: 1. Financial Express dated September 04, 2017- Mumbai Edition 2. Financial Express dated September 04, 2017- Ahmedabad Edition 3. Financial Express dated September 04, 2017- Ahmedabad Edition (Gujarati Language)
01-Sep-2017  Sun Pharmaceutical Industries Limited - AGM/Book Closure
Sun Pharmaceutical Industries Limited - AGM/Book Closure

Sun Pharmaceutical Industries Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from September 20, 2017 to September 26 , 2017(both days inclusive) for the purpose of Annual General Meeting of the Company is scheduled to be held on September 26, 2017.and Payment of dividend
01-Sep-2017  Sun Pharmaceutical Industries Limited - Shareholders meeting
Sun Pharmaceutical Industries Limited - Shareholders meeting

Sun Pharmaceutical Industries Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 26, 2017
16-Aug-2017  Other announcement of Sun Pharmaceutical Industrie
Other announcement of Sun Pharmaceutical Industrie

Approval of Scheme of Arrangement among Sun Pharma Medisales Private Limited, Ranbaxy Drugs Limited, Gufic Pharma Limited, Vidyut Investments Limited and the Company and their respective members and creditors from National Company Law Tribunal
16-Aug-2017  Sun Pharmaceutical Industries Limited - Amalgamation/Merger
Sun Pharmaceutical Industries Limited - Amalgamation/Merger

Sun Pharmaceutical Industries Limited has informed the Exchange regarding 'Approval of Scheme of Arrangement among Sun Pharma Medisales Private Limited, Ranbaxy Drugs Limited, Gufic Pharma Limited, Vidyut Investments Limited and the Company and their respective members and creditors'.
Incorporation Year 1993 
Registered Office Sun Pharma Advanced Res.Centre,Tandalja,
,
Gujarat-390020
Telephone 91-265-5515500 / 5515600 / 700 
Fax 91-265-2354897 
Chairman Israel Makov
Managing Director Dilip S Shanghvi
Company Secretary Sunil R Ajmera 
Auditor Deloitte Haskins & Sells LLP 
Face Value(Rs)
Market Lot
Listing MCX-SX,BSE,NSE 
Registrar Link Intime India Pvt Ltd
C-13 Pannalal Silk,Mills Cmpd LBS Marg,Bhandup West,Mumbai - 400 078 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS